Anthem Biosciences Pvt. Ltd.

Anthem Biosciences Pvt. Ltd. , based in India, specializes in biologics and chemistry services that facilitate drug discovery and commercialization for pharmaceutical companies and research institutions. Founded in 2007 and headquartered in Bangalore, India, Anthem Biosciences Pvt.

Ltd. develops biologics and chemistry services, focusing on drug discovery. The founders - Ajay Bhardwaj, Ganesh Sambasivam, Muthupandi Sankarapandian, and Rupesh Kinekar - established the company to address critical challenges in life sciences. The company has completed four investment deals, with the latest being a BUYOUT in January 2021, where True North acquired a 10% minority stake for INR 6177.

3 million. This funding has supported the expansion of Anthem's capabilities. Anthem Biosciences offers biologics, chemistry, and biology services to accelerate drug discovery and commercialization. Their core services include gene design, advanced assay development, and biologics manufacturing, catering to pharmaceutical companies and research institutions.

This enables clients to enhance their research and development capabilities while addressing critical challenges in the life sciences sector. In the most recent fiscal year, 2023, Anthem Biosciences generated revenue of INR 131,691,510. 2 with an EBITDA of INR 67,116,089. 9.

The revenue primarily stems from service contracts and partnerships with clients, structured around project-based agreements that include milestone payments for ongoing projects. Anthem Biosciences aims to leverage recent funding to expand its operational capacity and capabilities. The acquisition by True North will facilitate this growth, allowing for the development of new products and services. The company is focusing on entering new markets, specifically targeting regions in North America and Europe by the end of 2024, to broaden its client base and enhance its service offerings.